Skip to main content

Renowned Scientist Christopher Mason, Ph.D. and Quantum-Si Collaborate for Exclusive GenomeWeb Webinar

Quantum-Si Incorporated (NASDAQ: QSI):

WHAT: Esteemed scientist Christopher Mason, Ph.D., of Weill Cornell Medicine, is set to discuss his Two Frontiers Project during an exclusive webinar hosted by GenomeWeb. Dr. Mason will also reveal his plans for using Quantum-Si’s benchtop protein sequencer, Platinum® to expand his multiomic research on extremophiles and what is needed for human survival in extreme environments.

WHY: Dr. Mason recently remarked, “To better understand disease and health, we must not only look at nucleic acids, but also other molecules and pivotal proteins. In recent years, the field of proteomics has surged forward. We are now experiencing a remarkable acceleration with advancements in protein sequencing, revealing new biology and post-translational modifications.”

WHO: The webinar will feature:

  • Christopher Mason, Ph.D., Professor of Genomics, Physiology, and Biophysics at Weill Cornell Medicine
  • Kenneth Skinner, Ph.D., Staff Scientist, Quantum-Si

WHEN: The webinar, titled “Characterizing Far-Flung Extremophiles with Next-Generation Protein Sequencing™,” will take place on Wednesday, February 28, at 11:00 a.m. ET.

WHERE: Hosted online by GenomeWeb. Reserve your spot today:

About Quantum-Si Incorporated

Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at or follow us on LinkedIn or X.

About Christopher Mason, Ph.D.

Christopher Mason, Ph.D., is a Professor of Genomics, Physiology, and Biophysics at Weill Cornell Medicine and the director of the WorldQuant Initiative for Quantitative Prediction. With over 300 peer-reviewed papers, five patents, and the foundation of numerous biotechnology companies and non-profits, Dr. Mason is a leading figure in genomics and predictive algorithms for medicine. He is also the author of “The Next 500 Years: Engineering Life to Reach New Worlds.”


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.